ICON plc on Thursday announced its acquisition of the Mapi Group.
ICON “specializes in the strategic development, management and analysis of programs that support clinical development,” according to a press release.
ICON says it hopes to bolster its Commercialization and Outcomes Research business by “adding significant commercialization presence, analytics, real world evidence generation and strategic regulatory expertise.”
“The late phase CRO market continues to grow as our customers face greater scrutiny from regulators and reimbursement bodies around real-world evidence of product value and safety,” ICON Chief Executive Officer Steve Cutler said. “The acquisition of Mapi extends the breadth and depth of ICON’s late phase capabilities … .”
Dublin-based ICON has 84 locations in 38 countries with roughly 12,000 employees.